Do you have patients with a history of cardiac events and difficult to treat cholesterolemia? 

Consider these resources from SCAI on PCSK9 inhibitors: 

Featuring Michael Davidson, MD from the University of Chicago Pritzker School of Medicine on “LDL Management: Guideline Recommendations,” covering the 2018 AHA/ACC Multicity Guideline on the Management of Blood Cholesterol.  

Other topics include: 

• Case Presentation, Emmanouil S. Brilakis, MD, PhD, FSCAI 
• The Impact of PCSK-9 Inhibition of Coronary Plaque: GLAGOV and Beyond, Subhash Banerjee, MD, FSCAI,  
• PCSK-9 Inhibition: Clinical Trial Data, Payal Kohli, MD 
• Lipid Lowering in the COVID Era, Thomas Knickelbine, MD, FSCAI

This activity is sponsored by SCAI and supported by Amgen.